Press Releases
ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today t [...]
Press Releases
ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting
The biomarker is the first to predict long-term ADT usage in men with high-risk localized prostate cancer.
Press Releases
ArteraAI and American Cancer Society Announce New Relationship
ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, and the American [...]
Press Releases
ArteraAI Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI
ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launched publicly [...]
Press Releases
Our science was presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18.
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate C [...]